Company news
Aoti, Inc. (LSE:AOTI) news
Every Aoti, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Director/PDMR Shareholding - ESPP
August 4, 2026
Trading Statement
July 27, 2026
AOTI achieves transformational milestone
July 24, 2026
Director/PDMR Shareholding – Share purchase
June 19, 2026
Employee Share Purchase Plan
May 1, 2026
Real-world study of AOTI’s TWO2® therapy
April 27, 2026
Grant of awards under Long Term Incentive Plan
April 23, 2026
2025 Annual Report and Notice of AGM
April 21, 2026
Director/PDMR Shareholding
April 2, 2026
Final Results
March 30, 2026
Full Year Trading Update and Notice of Results
February 23, 2026
Holding(s) in Company
December 15, 2025
Appointment of Joint Corporate Broker
October 6, 2025
2025 Interim Results
September 22, 2025
Notice of Results
September 8, 2025
NICE fast track recommendation for Topical Oxygen
September 3, 2025
Results of Placing
July 31, 2025
Proposed Placing in AOTI Inc.
July 30, 2025
California Medicaid Provider ID Awarded
July 21, 2025
Result of AGM
June 25, 2025
AOTI unlocks broad market access in Germany
June 23, 2025
End of Distribution Compliance Period
June 18, 2025
2024 Annual Report and Notice of AGM
May 27, 2025
Presentation at AJ Bell and Shares Spotlight Event
May 19, 2025
Director Shareholding - Share Purchase
May 13, 2025
2024 Final Results
April 28, 2025
Investor Presentation via Investor Meet Company
April 23, 2025
TWO2® in NHS supply chain framework agreement
April 22, 2025
Notification of Major Holdings
April 9, 2025
Trading Update for the year ended 31 December 2024
February 12, 2025
CORRECTION New Medicaid states, coverage expansion
January 24, 2025
New Medicaid states, payer coverage expansion
January 9, 2025
Grant of performance share awards under LTIP
December 17, 2024
Enrolment Commences for VLU Clinical Trial
December 16, 2024
5 Year Veterans Administration Contract Extension
December 12, 2024
CMS Topical Oxygen Therapy coverage review
November 11, 2024
2024 Interim Results
September 16, 2024
Pre-close Trading Update
August 15, 2024
US FDA 510(k) Clearance of NEXATM NPWT System
July 29, 2024
Admission to AIM and First Day of Dealings
June 18, 2024